Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

Merck and Eisai reported new data for a drug regimen of Keytruda and Lenvima. Elsewhere, AstraZeneca expanded in Canada and ...

The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

NEW YORK, January 16, 2025--PESG Releases a Market Update - Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech advancing RNA interference (RNAi) therapies for KRAS-driven cancers ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

[28] RNA interference (RNAi) is a naturally occurring biological pathway in which small, double-stranded RNA molecules suppress gene expression in an exquisitely sequence-specific manner Exogenous ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal ...

With its International Headquarters in Zug, Switzerland, Alnylam has become a key part of the Swiss biotech environment.

The senior author is Roger Innes, Distinguished Professor of Biology. "What excites us most about this discovery is that it indicates plants may control their microbiomes, in part, by regulating gene ...

The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.